Craig Hallum Lowers scPharmaceuticals (NASDAQ:SCPH) Price Target to $12.00

scPharmaceuticals (NASDAQ:SCPH) had its price objective trimmed by Craig Hallum from $16.00 to $12.00 in a report released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Monday, August 19th.

scPharmaceuticals Stock Performance

Shares of SCPH stock traded down $0.27 during trading on Thursday, reaching $3.09. 658,346 shares of the company’s stock traded hands, compared to its average volume of 266,770. scPharmaceuticals has a 1 year low of $3.08 and a 1 year high of $6.71. The company has a market capitalization of $154.59 million, a P/E ratio of -1.63 and a beta of 0.15. The company has a current ratio of 4.84, a quick ratio of 3.66 and a debt-to-equity ratio of 4.32. The firm’s 50-day moving average is $4.53 and its 200 day moving average is $4.50.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.44). The business had revenue of $8.05 million for the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative return on equity of 263.11% and a negative net margin of 264.60%. Equities research analysts expect that scPharmaceuticals will post -1.34 EPS for the current year.

Institutional Trading of scPharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Suvretta Capital Management LLC bought a new stake in scPharmaceuticals during the 3rd quarter valued at $9,343,000. Rubric Capital Management LP raised its stake in shares of scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after acquiring an additional 1,250,000 shares during the last quarter. King Luther Capital Management Corp boosted its holdings in shares of scPharmaceuticals by 51.8% during the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after purchasing an additional 752,005 shares during the period. Stonepine Capital Management LLC grew its stake in shares of scPharmaceuticals by 84.7% in the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after purchasing an additional 357,171 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in scPharmaceuticals during the 2nd quarter valued at about $1,544,000. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.